CAR T cells and non–CAR T cells in samples from baseline and after pembrolizumab, analyzed separately. (A) t-SNE plots of CAR T cells in responders and nonresponders, before and after pembrolizumab therapy, using phenograph analysis. (B) Boxplot showing frequencies of each of the defined clusters in panel A. (C) Composition of cluster 17 CAR T cells after marker normalization. (D) t-SNE plots of non–CAR T cells in responders and nonresponders, before and after pembrolizumab therapy, using Phenograph analysis. (E) Boxplot showing frequencies of each of the defined clusters in panel D. (C) Composition of cluster 17 and 18 non–CAR T cells after marker normalization. Patients with clinical benefit at 3 months are grouped as responders, and patients with PD at 3 months are grouped as nonresponders.